Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Aug 29, 2017 2:09pm
65 Views
Post# 26633405

RE:Share dumping

RE:Share dumpingI don't think so. I think this is mostly all do to liquitiy or lack there of. This is so thinly traded right now anyone selling a bit will drop the price. Pretty much everyone is in the same boat as us and parked their shares till January. Look at the volume traded today, 156,000, but what does that mean? It's only $12,480 dollars traded.
Let's look at the dollars traded fror the past week:
Aug 29 - $12,480.00
Aug 28 - $1,742.50
Aug 25 - $1,678.75
Aug 24 - $2,737.00
Aug 23 - $17,082.00
Aug 22 - $720.00
Aug 11 - $5,691.18

That's $42,121 in 7 days or averaging $6,000 a day. Volume is virtually nothing. Volatility is due to this. As I said before, the real target is January. Everything between now and then doesn't matter (unless they have a catastrophic failure whch my due dilligence says the likelyhood is very low). I will sit and wait till January. Then I will cash in and everyone who solid in a panic will regret it.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities